Polycystic Ovary Syndrome Clinical Trial
— 11OXO-PCOSOfficial title:
The Role of 11-oxygenated Androgens in Androgen Excess and Metabolic Dysfunction of Women With Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) affects 10% of all women and usually presents with irregular menstrual periods and difficulties conceiving. It is also a lifelong metabolic disorder and affected women have an increased risk of type 2 diabetes, high blood pressure, and heart disease. Increased blood levels of male hormones, also termed androgens, are found in most PCOS patients. Androgen excess appears to impair the ability of the body to respond to the sugar-regulating hormone insulin (also termed 'insulin resistance'). Androgens circulating in the blood in women with PCOS are comprised of classic androgens (for example testosterone), and the less-characterised 11-oxygenated androgen subclass that arises from the adrenal glands. The investigators have recently demonstrated that 11-oxygenated androgens make up the majority of circulating androgens in women with PCOS. In preliminary studies using minimally invasive adipose tissue sampling, the investigators have found that the fat tissue of women with PCOS overproduces classic androgens. This can lead directly to disturbances in the ability of fat cells to store fat effectively (lipotoxicity), resulting in insulin resistance and the consequent risk of liver damage. However, there are no published studies on in vivo androgen concentrations in the adipose tissue of women with PCOS. Furthermore, the scientific community do not have any information on whether adipose concentrations of 11-oxygenated androgens are also increased in women with PCOS. Research Questions The investigators aim to examine the metabolism of classic and 11-oxygenated androgens in detail in both circulations and in the adipose tissue of women with PCOS. The investigators will examine how precursor variants of both 11-oxygenated and classic androgens, which are converted by the body into active hormones, are broken down (metabolised) within the adipose tissue of women with PCOS. The investigators will also investigate if the 11-oxygenated androgens have a differential impact on metabolic function as compared to classic androgens. This will give important insights into the adipose tissue metabolome in women with PCOS, and how locally generated androgens impact on adipose tissue function and metabolic risk.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | May 30, 2025 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility | Part A Inclusion Criteria: - BMI between 30-40 kg/m2 - Age range 18-40 years - Ability to provide informed consent For women participating in the PCOS group, the diagnosis of PCOS will be established during their recruitment to DAISy-PCOS study on the basis of the Rotterdam Consensus Criteria for the Diagnosis of PCOS, as recommended by the current international PCOS guidelines (at least 2 out of 3 criteria): - Androgen excess (clinical and/or biochemical evidence) - Chronic oligo-/anovulation (clinical and/or biochemical evidence) - Polycystic appearance of the ovaries on ultrasound (according to the most recent guidelines (10), taking into account the higher resolution capacity of modern ultrasound, the presence of ovarian PCOS morphology is defined as follows: 20 or more follicles of 2-9mm in diameter and/or an increased ovarian volume >10 millilitre [without a cyst or dominant follicle] in either ovary) In addition, we will perform clinical and/or biochemical exclusion, as appropriate, of other conditions that could explain the above manifestation (e.g. congenital adrenal hyperplasia, Cushing's syndrome, Prolactinoma, adrenal and gonadal tumours) Exclusion Criteria: - Pregnancy or breastfeeding at the time of planned recruitment - History of significant renal (eGFR<30) or hepatic impairment (aspartate aminotransferase or alanine transaminase >two-fold above ULN; pre-existing bilirubinaemia >1.2 ULN) - Any other significant disease or disorder that, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study. - Participants who have participated in another research study involving an investigational medicinal product in the 12 weeks preceding the planned recruitment - Glucocorticoid use via any route within the last six months - Current intake of drugs known to impact upon steroid synthesis or metabolism or on metabolic function or intake of such drugs during the six months preceding the planned recruitment - Use of oral or transdermal hormonal contraception in the three months preceding the planned recruitment - Use of contraceptive implants in the twelve months preceding the planned recruitment - Allergy or intolerance to any of the ingredients in the high fat meal, or any of the ingredients in the dehydroepiandrosterone and 11-ketoandrostenedione preparations. - Diabetes or impaired glucose metabolism Part B Inclusion criteria - Women undergoing elective, abdominal, non-cancer surgery - Age range 18-70 years - Ability to provide informed consent Exclusion criteria - Pregnancy or breastfeeding at the time of planned recruitment - Glucocorticoid use via any route within the last six months - Current intake of drugs known to impact upon steroid synthesis or metabolism or on metabolic function or intake of such drugs during the six months preceding the planned recruitment - Type 1 diabetes - Medical treatment of type 2 diabetes |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Institute of Metabolism and Systems Research | Birmingham | West Midlands |
Lead Sponsor | Collaborator |
---|---|
University of Birmingham |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline height | During Visit 1, the research team will measure height in centimetres | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline weight | During Visit 1, the research team will measure weight in kilogram | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline body mass index (BMI) | During Visit 1, weight and height will be combined to report BMI in kg/m^2 | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline waist circumference | During Visit 1, the research team will measure Waist circumference to nearest centimetre | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline blood pressure | During Visit 1, the research team will measure both systolic and diastolic Blood pressure in mmHg after 10 minutes in sitting position | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline urea & electrolytes | During Visit 1, the research team will collect blood to measure urea & electrolytes in mmol/L | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline liver function test | During Visit 1, the research team will collect blood to measure liver function tests in mmol/L | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline haemoglobin | During Visit 1, the research team will collect blood to measure haemoglobin in grams per litre | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline white cell and platelet count | During Visit 1, the research team will collect blood to measure White cell and platelets in number of cells per ml | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline lipid profile | During Visit 1, the research team will collect blood to measure lipid profile in mmol/L | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline glucose | During Visit 1, the research team will collect blood to measure glucose in mmol/L | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline glycated haemoglobin | During Visit 1, the research team will collect blood to measure glycated haemoglobin (HbA1c) in mmol/mol | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline thyroid function test | During Visit 1, the research team will collect blood to measure thyroid function test in mIU/L | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline Dehydroepiandrosterone (DHEAS) | During Visit 1, the research team will collect blood to measure DHEAS in µmol/L | 3 years | |
Primary | overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline androstenedione | During Visit 1, the research team will collect blood to measure androstenedione in µmol/L | 3 years | |
Primary | overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline testosterone | During Visit 1, the research team will collect blood to measure testosterone in nmol/L | 3 years | |
Primary | overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline sex hormone binding globulin | During Visit 1, the research team will collect blood to measure sex hormone binding globulin in nmol/L | 3 years | |
Primary | overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline 17-hydroxyprogesterone | During Visit 1, the research team will collect blood to measure 17-hydroxyprogesterone in nmol/L | 3 years | |
Primary | overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline prolactin | During Visit 1, the research team will collect blood to measure prolactin in mIU/L | 3 years | |
Primary | overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline Follicle-stimulating hormone | During Visit 1, the research team will collect blood to measure Follicle-stimulating hormone in IU/L | 3 years | |
Primary | overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline luteinizing hormone | During Visit 1, the research team will collect blood to measure luteinizing hormone in IU/L | 3 years | |
Primary | overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline oestradiol | During Visit 1, the research team will collect approx 20 ml of blood to measure oestradiol in pmol/L. | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-understanding steroidal activity in peripheral blood mononuclear cells. | During Visit 1, the research team will collect approx 63 ml of blood to extract peripheral blood mononuclear cells for further experiments to measure the impact of classic and 11-oxygenated androgen precursors on downstream steroid profile | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism- to study the changes in steroid levels over time in arterialized hand vein | Visit 2 to 4, the research team will collect blood samples (1-2ml each time) from arterialized hand vein to study the changes in steroid levels from -90 to 480 min at 30 min intervals | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism- to study the changes in steroid levels over time in abdominal vein | Visit 2 to 4, the research team will collect blood samples (1-2ml each time) from abdominal vein to study the changes in steroid levels from -90 to 480 min at 30 min intervals | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism to study the changes in salivary steroid levels over time | Visit 2 to 4, the research team will collect salivary samples (1-2ml each time) to study the changes in steroid levels at 0, 30, and 60 minutes and hourly thereafter until the end of Study Visits. | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-to study the changes in urinary steroid levels over time | Visit 2 to 4, the research team will collect urine from time point 0 to 480 minutes to study the changes in steroid levels | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism-establishing baseline hormone levels for part B of the study | for Part B of the study, a blood sample (approx 7 ml) is collected from female volunteers undergoing elective abdominal surgery to establish baseline hormonal levels | 3 years | |
Primary | The impact of classic and 11-oxygenated androgen precursors on systemic circulation of overall steroid profile and its impact on lipid and glucose metabolism- to study the downstream conversion of steroid precursor in omental and subcutaneous fat | for Part B of the study, paired subcutaneous and omental adipose tissue samples (up to 5 g) are collected from female volunteers undergoing elective abdominal surgery.
the concentration of classic and 11-oxygenated androgen metabolites (androstenedione, testosterone, dihydrotestosterone, 11-ketoandrostenedione, 11-hydroxyandrostenedione, 11-ketotestosterone, 11-hydroxytestosterone) will be measured in the culture medium by liquid chromatography tandem mass spectrometery in nmol/L. the relative abundance of all detectable metabolites will be determined by untargeted metabolomics using liquid chromatography tandem mass spectrometery. the tissue will be used for gene expression analysis: Quantitative PCR will be used to determination of the relative abundance of specific mRNA transcripts. RNAseq will be used to quantify the abundace of all mRNA transcripts of the transciptome. |
3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03142633 -
MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
|
||
Completed |
NCT06158932 -
A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04932070 -
Berberine and Polycystic Ovary Syndrome
|
N/A | |
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT03480022 -
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
|
Phase 3 | |
Active, not recruiting |
NCT03043924 -
Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)
|
N/A | |
Completed |
NCT05246306 -
Aerobic Capacity and Physical Fitness Level of Adolescents With PCOS
|
||
Completed |
NCT05981742 -
Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS
|
Phase 2 | |
Completed |
NCT05702957 -
Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT05029492 -
Effect of Visceral Manipulation on PCOS
|
N/A | |
Completed |
NCT02924025 -
Motivational Interviewing as an Intervention for PCOS
|
N/A | |
Not yet recruiting |
NCT02255578 -
Endobarrier Treatment in Women With PCOS
|
Phase 3 | |
Withdrawn |
NCT01638988 -
Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin
|
Phase 3 | |
Not yet recruiting |
NCT00883259 -
Metformin and Gestational Diabetes in High-risk Patients: a RCTs
|
Phase 4 | |
Completed |
NCT02098668 -
Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON
|
N/A | |
Completed |
NCT01462864 -
Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome
|
N/A | |
Recruiting |
NCT01431352 -
Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS)
|
N/A | |
Completed |
NCT00989781 -
Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
|
N/A |